| Project/Area Number |
20591185
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
HANAWA Haruo Niigata University, 医歯学系, 講師 (40282983)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
小玉 誠 新潟大学, 医歯学系, 准教授 (10242447)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 臨床免疫学 / 生物学的製剤 / 遺伝子治療 / IL-1 / 徙免疫疾患 / IL-1受容体-Igヘテロダマー / アナキンラ / 鉄代謝 / ヘム / 内因性リガンド / 自己免疫疾患 / IL-1受容体-Igヘテロダイマー |
|---|
| Research Abstract |
Interleukin (IL)-1 inhibitor may be a candidate anti-inflammatory drug. We examined the effect of a heterodimer of IL-1 receptor accessory protein (Acp)-immunoglobulin (Ig) and IL-1R type II (IL1R2)-Ig named AcP-Ig/IL1R2-Ig heterodimer, and compared its effects with other IL-1 inhibitors reported previously. Our results demonstrated that the AcP-Ig/IL1R2-Ig heterodimer (rat, IC50=1.95 pM ; human, IC50=0.14 pM) inhibited IL-1 response to a greater extent than IL1RA (rat, IC50=1,935 pM), Acp-IL1R type I (IL1R1)-Ig homodimer (rat, IC50=73.7 pM ; human, IC50=4.48 pM) and Acp-IL1R2-Ig homodimer (rat IC50=72.8 pM) and strongly inhibited responses of both IL-1α and IL-1β.
|
